Insider Selling: Penumbra, Inc. (NYSE:PEN) CFO Sells $572,000.00 in Stock

Penumbra, Inc. (NYSE:PEN) CFO Maggie Yuen sold 2,000 shares of Penumbra stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $286.00, for a total value of $572,000.00. Following the completion of the sale, the chief financial officer now directly owns 15,243 shares in the company, valued at $4,359,498. This represents a 11.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Penumbra Trading Down 0.9 %

Shares of Penumbra stock opened at $275.07 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The company has a market capitalization of $10.59 billion, a P/E ratio of 809.01, a P/E/G ratio of 2.83 and a beta of 0.53. The business has a 50 day moving average price of $267.39 and a 200 day moving average price of $235.14.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Sell-side analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. True Wealth Design LLC acquired a new position in Penumbra in the 3rd quarter valued at $26,000. UMB Bank n.a. raised its holdings in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares during the last quarter. Hurley Capital LLC acquired a new position in Penumbra in the 4th quarter valued at $56,000. Huntington National Bank raised its holdings in Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after acquiring an additional 154 shares during the last quarter. Finally, Mather Group LLC. raised its holdings in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after acquiring an additional 208 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citigroup lifted their price objective on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Oppenheimer assumed coverage on Penumbra in a report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price objective on the stock. Canaccord Genuity Group lifted their price objective on Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Morgan Stanley lifted their price objective on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Finally, Wells Fargo & Company lifted their price target on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Penumbra presently has a consensus rating of “Moderate Buy” and an average price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.